ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Is radiotherapy still an option for residual retroperitoneal masses in stage IIC seminoma?
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn patients with clinical stage IIC seminoma, residual retroperitoneal masses are detected in up to 80% of patients after chemotherapy. Lesions < 3 cm are generally monitored; however, the management of patients with residuals > 3 cm remains a matter of debate. Herein, we present a case series of these patients who underwent radiotherapy (RT) and discuss the role of RT in these cases.
methodsThree patients with de novo and two patients with relapsed stage IIC seminoma who underwent RT for retroperitoneal residual masses after chemotherapy at two centers between 2014 and 2025 were retrospectively evaluated. All treatment decisions were made by a multidisciplinary board.
resultsThe median age of the patients was 43 (26-47) years, and the median follow-up was 30 (10-120) months. Following radical orchiectomy, all patients received 3-4 cycles of BEP chemotherapy. The median size of the post-chemotherapy residual was 6.5 (3.2-8.5) cm. PET-CT was positive with SUVmax > 3 for all patients. Two patients received only paraaortic RT, three patients received paraaortic + ipsilateral pelvic lymph node RT with a total dose of 25.5 Gy. An additional dose of 10 Gy was prescribed to the residual mass. All treatments were implemented with intensity-modulated radiotherapy (IMRT). Three patients experienced grade 1 nausea. No recurrence or secondary malignancy was detected at final follow-up.
conclusionRadiotherapy may be considered as a potential non-invasive option for managing residual retroperitoneal masses after chemotherapy in stage IIC seminoma, particularly in patients with a high risk of recurrence and in whom retroperitoneal lymph node dissection (RPLND) is anticipated to be associated with morbidity.
Indexed as
Identifiers
42048012What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.